HHLA2 as a novel inhibitor of human immune system and uses thereof
View Patent ↗Provided are methods of treating an autoimmune disease in a subject, or of suppressing transplant rejection in a subject, or of treating a cancer in a subject, as well as compositions therefor.
1. A method of treating a HHLA2-bearing tumor in a subject, comprising administering to the subject an amount of an anti-HHLA2antibody, or an HHLA2-binding fragment of an anti-HHLA2antibody, effective to treat the HHLA2-bearing tumor.
2. The method of claim 1 , wherein the HHLA2 to which the anti-HHLA2antibody is directed is a human HHLA2 protein.
3. The method of claim 1 , wherein the HHLA2 protein comprises consecutive amino acid residues having the sequence set forth in SEQ ID NO: 1.
4. The method of claim 1 , wherein the antibody is a humanized antibody, a chimeric antibody or an isolated human antibody.
5. The method of claim 1 , wherein the antibody is a monoclonal antibody.
6. The method of claim 1 , wherein the anti-HHLA2 antibody or HHLA2-binding fragment is conjugated to a cytotoxic agent, an anti-cancer drug or a chemotherapeutic agent.
7. The method of claim 1 , wherein the HHLA2-bearing tumor is a HHLA2-bearing tumor of breast, esophagus, liver, lung, bladder, colon or rectum, ovary, thyroid, pancreas, kidney, prostate, or is a malignant melanoma.